<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>17(2)</volume><submitter>Xu N</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>This study aims to evaluate the efficacy of the standard agglutination test (SAT), the Brucellacapt test and enzyme-linked immunosorbent assay (ELISA) in clinical specimens collected from patients with suspected brucellosis.&lt;h4>Methods&lt;/h4>A prospective study was conducted from December 2020 to December 2021. Brucellosis was diagnosed on the basis of clinical evidence, and confirmed by isolation of Brucella or a four-fold rise in SAT titer. All samples were tested by the SAT, ELISA and the Brucellacapt test. Titers ≥1:100 were considered as SAT positive; ELISA was considered positive when an index greater than 11 was detected, while titers ≥1/160 indicated positivity on the Brucellacapt test. The specificity, sensitivity, and positive (PPVs) and negative predictive value</pubmed_abstract><journal>PLoS neglected tropical diseases</journal><pagination>e0011131</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9942959</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Evaluating the efficacy of serological testing of clinical specimens collected from patients with suspected brucellosis.</pubmed_title><pmcid>PMC9942959</pmcid><pubmed_authors>Yang H</pubmed_authors><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>Qu C</pubmed_authors><pubmed_authors>Xu N</pubmed_authors><pubmed_authors>Yang L</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Sai L</pubmed_authors><pubmed_authors>Wen S</pubmed_authors><pubmed_authors>Wang G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Evaluating the efficacy of serological testing of clinical specimens collected from patients with suspected brucellosis.</name><description>&lt;h4>Background&lt;/h4>This study aims to evaluate the efficacy of the standard agglutination test (SAT), the Brucellacapt test and enzyme-linked immunosorbent assay (ELISA) in clinical specimens collected from patients with suspected brucellosis.&lt;h4>Methods&lt;/h4>A prospective study was conducted from December 2020 to December 2021. Brucellosis was diagnosed on the basis of clinical evidence, and confirmed by isolation of Brucella or a four-fold rise in SAT titer. All samples were tested by the SAT, ELISA and the Brucellacapt test. Titers ≥1:100 were considered as SAT positive; ELISA was considered positive when an index greater than 11 was detected, while titers ≥1/160 indicated positivity on the Brucellacapt test. The specificity, sensitivity, and positive (PPVs) and negative predictive value</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-18T14:11:34.725Z</modification><creation>2025-02-18T22:55:21.04Z</creation></dates><accession>S-EPMC9942959</accession><cross_references><pubmed>36802393</pubmed><doi>10.1371/journal.pntd.0011131</doi></cross_references></HashMap>